NO315472B1 - Tumor, karbohydratantigen spesifikt monoklonalt antistoff og cellelinje, farmasöytisk sammensetning og fremgangsmåte for invitro diagnostikk - Google Patents
Tumor, karbohydratantigen spesifikt monoklonalt antistoff og cellelinje, farmasöytisk sammensetning og fremgangsmåte for invitro diagnostikk Download PDFInfo
- Publication number
- NO315472B1 NO315472B1 NO19934777A NO934777A NO315472B1 NO 315472 B1 NO315472 B1 NO 315472B1 NO 19934777 A NO19934777 A NO 19934777A NO 934777 A NO934777 A NO 934777A NO 315472 B1 NO315472 B1 NO 315472B1
- Authority
- NO
- Norway
- Prior art keywords
- antibody
- monoclonal antibody
- cell line
- cells
- antigen
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 34
- 102000036639 antigens Human genes 0.000 title claims abstract description 34
- 108091007433 antigens Proteins 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 206010028980 Neoplasm Diseases 0.000 title description 15
- 150000001720 carbohydrates Chemical class 0.000 title description 5
- 210000004027 cell Anatomy 0.000 claims abstract description 64
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 23
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 4
- 230000002269 spontaneous effect Effects 0.000 claims abstract 2
- 230000027455 binding Effects 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 abstract description 3
- 239000002299 complementary DNA Substances 0.000 description 28
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 238000011534 incubation Methods 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000012202 endocytosis Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 101100191768 Caenorhabditis elegans pbs-4 gene Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- NGYHUCPPLJOZIX-XLPZGREQSA-N 5-methyl-dCTP Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NGYHUCPPLJOZIX-XLPZGREQSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 1
- SITWEMZOJNKJCH-WDSKDSINSA-N Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SITWEMZOJNKJCH-WDSKDSINSA-N 0.000 description 1
- QYLJIYOGHRGUIH-CIUDSAMLSA-N Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N QYLJIYOGHRGUIH-CIUDSAMLSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 239000010755 BS 2869 Class G Substances 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 108050009160 DNA polymerase 1 Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 206010051925 Intestinal adenocarcinoma Diseases 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- QXOHLNCNYLGICT-YFKPBYRVSA-N Met-Gly Chemical compound CSCC[C@H](N)C(=O)NCC(O)=O QXOHLNCNYLGICT-YFKPBYRVSA-N 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- GLUBLISJVJFHQS-VIFPVBQESA-N Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 GLUBLISJVJFHQS-VIFPVBQESA-N 0.000 description 1
- NYQBYASWHVRESG-MIMYLULJSA-N Phe-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 NYQBYASWHVRESG-MIMYLULJSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- UYKREHOKELZSPB-JTQLQIEISA-N Trp-Gly Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(O)=O)=CNC2=C1 UYKREHOKELZSPB-JTQLQIEISA-N 0.000 description 1
- IMMPMHKLUUZKAZ-WMZOPIPTSA-N Trp-Phe Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=CC=C1 IMMPMHKLUUZKAZ-WMZOPIPTSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000005550 amino acid supplement Nutrition 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- ZYWFEOZQIUMEGL-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol;phenol Chemical compound ClC(Cl)Cl.CC(C)CCO.OC1=CC=CC=C1 ZYWFEOZQIUMEGL-UHFFFAOYSA-N 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000018554 digestive system carcinoma Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007973 glycine-HCl buffer Substances 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- STKYPAFSDFAEPH-LURJTMIESA-N glycylvaline Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CN STKYPAFSDFAEPH-LURJTMIESA-N 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- CIJQGPVMMRXSQW-UHFFFAOYSA-M sodium;2-aminoacetic acid;hydroxide Chemical compound O.[Na+].NCC([O-])=O CIJQGPVMMRXSQW-UHFFFAOYSA-M 0.000 description 1
- IGHGOYDCVRUTSU-UHFFFAOYSA-M sodium;2-hydroxypropane-1,2,3-tricarboxylic acid;hydroxide Chemical compound [OH-].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O IGHGOYDCVRUTSU-UHFFFAOYSA-M 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9102074A SE9102074D0 (sv) | 1991-07-03 | 1991-07-03 | Tomour antigen specific antibody |
| PCT/SE1992/000502 WO1993001303A1 (en) | 1991-07-03 | 1992-07-03 | Tumor, carbohydrate antigen specific monoclonal antibody and cell line |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO934777D0 NO934777D0 (no) | 1993-12-22 |
| NO934777L NO934777L (no) | 1994-02-11 |
| NO315472B1 true NO315472B1 (no) | 2003-09-08 |
Family
ID=20383243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19934777A NO315472B1 (no) | 1991-07-03 | 1993-12-22 | Tumor, karbohydratantigen spesifikt monoklonalt antistoff og cellelinje, farmasöytisk sammensetning og fremgangsmåte for invitro diagnostikk |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5552293A (ko) |
| EP (1) | EP0521842B1 (ko) |
| JP (1) | JP3194020B2 (ko) |
| KR (1) | KR100246681B1 (ko) |
| AT (1) | ATE171193T1 (ko) |
| AU (2) | AU658198B2 (ko) |
| CA (1) | CA2073124C (ko) |
| DE (1) | DE69226990T2 (ko) |
| DK (1) | DK0521842T3 (ko) |
| EE (1) | EE03031B1 (ko) |
| ES (1) | ES2124250T3 (ko) |
| FI (1) | FI109207B (ko) |
| HU (2) | HU218084B (ko) |
| IE (1) | IE80841B1 (ko) |
| IL (1) | IL102390A (ko) |
| NO (1) | NO315472B1 (ko) |
| NZ (1) | NZ243435A (ko) |
| SE (1) | SE9102074D0 (ko) |
| WO (2) | WO1993001302A1 (ko) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9402430L (sv) | 1994-07-11 | 1996-01-12 | Pharmacia Ab | Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten |
| SE9601245D0 (sv) | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
| TW517061B (en) | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
| EP2266607A3 (en) | 1999-10-01 | 2011-04-20 | Immunogen, Inc. | Immunoconjugates for treating cancer |
| EP1411962B1 (en) * | 2001-03-15 | 2011-01-19 | Neogenix Oncology, Inc. | Monoclonal antibody therapy for pancreas cancer |
| DE10116552A1 (de) * | 2001-04-03 | 2002-10-10 | Abc Armbruster Biochemicals | Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe |
| EP1539239A4 (en) * | 2002-07-02 | 2005-09-14 | Smithkline Beecham Corp | NEW STABLE FORMULATION |
| US7390898B2 (en) | 2002-08-02 | 2008-06-24 | Immunogen Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| EP3851126A1 (en) | 2003-05-20 | 2021-07-21 | ImmunoGen, Inc. | Maytansinoid-cell-binding agent conjugates |
| AU2006213662B2 (en) * | 2005-02-11 | 2010-08-05 | Immunogen, Inc. | Process for preparing stable drug conjugates |
| US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
| NZ566245A (en) * | 2005-08-11 | 2012-04-27 | Matossian Rogers Arpi | Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease |
| AU2012244244B2 (en) * | 2005-08-11 | 2015-08-27 | Arpi Matossian-Rogers | TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease |
| ES2533992T3 (es) | 2005-08-24 | 2015-04-16 | Immunogen, Inc. | Procedimiento para preparar conjugados de anticuerpo maitansinoide |
| RU2519089C2 (ru) | 2008-08-05 | 2014-06-10 | Торэй Индастриз, Инк. | Способ обнаружения злокачественных опухолей |
| KR102444399B1 (ko) | 2009-06-03 | 2022-09-16 | 이뮤노젠 아이엔씨 | 메이탄시노이드의 제조방법 |
| MY171008A (en) | 2011-03-29 | 2019-09-23 | Immunogen Inc | Preparation of maytansinoid antibody conjugates by a one-step process |
| UA116524C2 (uk) | 2011-03-29 | 2018-04-10 | Іммуноджен, Інк. | Спосіб одержання кон'югата антитіло-майтансиноїд |
| RU2661083C2 (ru) | 2012-10-04 | 2018-07-11 | Иммуноджен, Инк. | Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент |
| WO2015076425A1 (ja) * | 2013-11-25 | 2015-05-28 | リンク・ジェノミクス株式会社 | 新規モノクローナル抗体 |
| CA2966932A1 (en) | 2014-11-19 | 2016-05-26 | Immunogen, Inc. | Process for preparing cell-binding agent-cytotoxic agent conjugates |
| JP7161938B2 (ja) | 2016-01-10 | 2022-10-27 | ネオティーエックス セラピューティクス リミテッド | スーパー抗原媒介性癌免疫療法の能力を増強するための方法および組成物 |
| EP3411077A1 (en) | 2016-02-05 | 2018-12-12 | ImmunoGen, Inc. | Efficient process for preparing cell-binding agent-cytotoxic agent conjugates |
| CN107167590B (zh) * | 2017-04-14 | 2019-03-08 | 江苏福隆生物技术有限公司 | 糖类抗原242的板式化学发光法检测试剂盒及制备方法 |
| US20200256880A1 (en) * | 2017-08-16 | 2020-08-13 | The Broad Institute, Inc. | Neuronal Assay Method Involving Calcineurin |
| MX2021013908A (es) | 2019-05-15 | 2022-03-11 | Neotx Therapeutics Ltd | Tratamiento para el cáncer. |
| KR20220150353A (ko) | 2020-03-05 | 2022-11-10 | 네오티엑스 테라퓨틱스 엘티디. | 면역 세포를 사용하여 암을 치료하기 위한 방법 및 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4752569A (en) * | 1984-06-21 | 1988-06-21 | The Regents Of The University Of California | Sialylated Lewisx epitope, antibodies and diagnosis |
| US4904596A (en) * | 1985-08-07 | 1990-02-27 | Fred Hutchinson Cancer Research Center | Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside |
| SE8902043L (sv) * | 1988-11-10 | 1990-05-11 | Pharmacia Ab | Foerfarande foer karakterisering av makromolekyler |
| DK0610179T3 (da) * | 1990-07-20 | 1997-03-24 | Pharmacia & Upjohn Ab | Målspecifikke antistof-superantigenkonjugater og fremstilling deraf |
| EP0540612A1 (en) * | 1990-07-20 | 1993-05-12 | Pharmacia AB | Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures |
-
1991
- 1991-07-03 SE SE9102074A patent/SE9102074D0/xx unknown
-
1992
- 1992-07-02 IL IL10239092A patent/IL102390A/en not_active IP Right Cessation
- 1992-07-02 WO PCT/SE1992/000495 patent/WO1993001302A1/en active Search and Examination
- 1992-07-03 KR KR1019930704117A patent/KR100246681B1/ko not_active IP Right Cessation
- 1992-07-03 DK DK92850166T patent/DK0521842T3/da active
- 1992-07-03 WO PCT/SE1992/000502 patent/WO1993001303A1/en active IP Right Grant
- 1992-07-03 AT AT92850166T patent/ATE171193T1/de not_active IP Right Cessation
- 1992-07-03 HU HU9400011A patent/HU218084B/hu not_active IP Right Cessation
- 1992-07-03 NZ NZ243435A patent/NZ243435A/en not_active IP Right Cessation
- 1992-07-03 AU AU19425/92A patent/AU658198B2/en not_active Ceased
- 1992-07-03 IE IE922188A patent/IE80841B1/en not_active IP Right Cessation
- 1992-07-03 ES ES92850166T patent/ES2124250T3/es not_active Expired - Lifetime
- 1992-07-03 JP JP17584892A patent/JP3194020B2/ja not_active Expired - Lifetime
- 1992-07-03 AU AU22920/92A patent/AU2292092A/en not_active Abandoned
- 1992-07-03 CA CA002073124A patent/CA2073124C/en not_active Expired - Lifetime
- 1992-07-03 EP EP92850166A patent/EP0521842B1/en not_active Expired - Lifetime
- 1992-07-03 DE DE69226990T patent/DE69226990T2/de not_active Expired - Lifetime
-
1993
- 1993-12-22 NO NO19934777A patent/NO315472B1/no unknown
- 1993-12-31 FI FI935970A patent/FI109207B/fi not_active IP Right Cessation
-
1994
- 1994-11-16 EE EE9400328A patent/EE03031B1/xx not_active IP Right Cessation
-
1995
- 1995-05-08 US US08/438,123 patent/US5552293A/en not_active Expired - Lifetime
- 1995-06-20 HU HU95P/P00289P patent/HU211512A9/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU211512A9 (en) | 1995-11-28 |
| DK0521842T3 (da) | 1999-06-14 |
| KR100246681B1 (ko) | 2000-04-01 |
| ATE171193T1 (de) | 1998-10-15 |
| NZ243435A (en) | 1994-10-26 |
| AU1942592A (en) | 1993-01-07 |
| EP0521842A3 (ko) | 1994-01-26 |
| WO1993001303A1 (en) | 1993-01-21 |
| HUT71193A (en) | 1995-11-28 |
| IL102390A (en) | 1996-01-19 |
| EP0521842A2 (en) | 1993-01-07 |
| DE69226990T2 (de) | 1999-03-25 |
| IE922188A1 (en) | 1993-01-13 |
| AU658198B2 (en) | 1995-04-06 |
| IE80841B1 (en) | 1999-03-24 |
| IL102390A0 (en) | 1993-01-14 |
| SE9102074D0 (sv) | 1991-07-03 |
| FI935970A0 (fi) | 1993-12-31 |
| NO934777L (no) | 1994-02-11 |
| HU9400011D0 (en) | 1994-05-30 |
| ES2124250T3 (es) | 1999-02-01 |
| DE69226990D1 (de) | 1998-10-22 |
| CA2073124A1 (en) | 1993-01-04 |
| CA2073124C (en) | 2007-06-19 |
| EP0521842B1 (en) | 1998-09-16 |
| FI935970A (fi) | 1993-12-31 |
| HU218084B (hu) | 2000-05-28 |
| WO1993001302A1 (en) | 1993-01-21 |
| US5552293A (en) | 1996-09-03 |
| JP3194020B2 (ja) | 2001-07-30 |
| FI109207B (fi) | 2002-06-14 |
| JPH05276987A (ja) | 1993-10-26 |
| AU2292092A (en) | 1993-02-11 |
| NO934777D0 (no) | 1993-12-22 |
| EE03031B1 (et) | 1997-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO315472B1 (no) | Tumor, karbohydratantigen spesifikt monoklonalt antistoff og cellelinje, farmasöytisk sammensetning og fremgangsmåte for invitro diagnostikk | |
| JP6082673B2 (ja) | 特異的結合タンパク質およびその使用 | |
| CA2250080C (en) | Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications | |
| EP0721470B1 (en) | Monoclonal antibodies for use in diagnosis and treatment of colorectal cancer | |
| JP5608091B2 (ja) | 抗メソセリン抗体およびその使用 | |
| RU2266298C2 (ru) | Антитела к антигену эпителиальных опухолей желудочно-кишечного тракта человека, родственному альфа 6 бета 4 интегрину | |
| US20100240100A1 (en) | Human antibodies that have mn binding and cell adhesion-neutralizing activity | |
| WO1997034636A9 (en) | Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications | |
| EP3851455A1 (en) | Monoclonal antibody specifically binding human and monkey cd38 antigen, and preparation method therefor and application thereof | |
| WO2000032635A9 (en) | Tumor specific human monoclonal antibodies and methods of use | |
| CN113597432B (zh) | 抗EpCAM抗体及其应用 | |
| JPH09183799A (ja) | ヒト化モノクローナル抗体 |